Literature DB >> 33908371

Thyroid status regulates the tumor microenvironment delineating breast cancer fate.

Helena Andrea Sterle1, Ximena Hildebrandt1, Matías Valenzuela Álvarez2, María Alejandra Paulazo1, Luciana Mariel Gutierrez2, Alicia Juana Klecha1, Florencia Cayrol1, María Celeste Díaz Flaqué1, Cinthia Rosemblit1, María Laura Barreiro Arcos1, Lucas Colombo3, Marcela Fabiana Bolontrade2, Vanina Araceli Medina4, Graciela Alicia Cremaschi1.   

Abstract

The patient's hormonal context plays a crucial role in the outcome of cancer. However, the association between thyroid disease and breast cancer risk remains unclear. We evaluated the effect of thyroid status on breast cancer growth and dissemination in an immunocompetent mouse model. For this, hyperthyroid and hypothyroid Balb/c mice were orthotopically inoculated with triple-negative breast cancer 4T1 cells. Tumors from hyperthyroid mice showed an increased growth rate and an immunosuppressive tumor microenvironment, characterized by increased IL-10 levels and decreased percentage of activated cytotoxic T cells. On the other hand, delayed tumor growth in hypothyroid animals was associated with increased tumor infiltration of activated CD8+ cells and a high IFNγ/IL-10 ratio. Paradoxically, hypothyroid mice developed a higher number of lung metastasis than hyperthyroid animals. This was related to an increased secretion of tumor CCL2 and an immunosuppressive systemic environment, with increased proportion of regulatory T cells and IL-10 levels in spleens. A lower number of lung metastasis in hyperthyroid mice was related to the reduced presence of mesenchymal stem cells in tumors and metastatic sites. These animals also exhibited decreased percentages of regulatory T lymphocytes and myeloid-derived suppressor cells in spleens but increased activated CD8+ cells and the IFNγ/IL-10 ratio. Therefore, thyroid hormones modulate the cellular and cytokine content of the breast tumor microenvironment. A better understanding of the mechanisms involved in these effects could be a starting point for the discovery of new therapeutic targets for breast cancer.

Entities:  

Keywords:  antitumor immunity; breast cancer; hyperthyroidism; hypothyroidism; mesenchymal stem cells

Mesh:

Substances:

Year:  2021        PMID: 33908371     DOI: 10.1530/ERC-20-0277

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  3 in total

1.  Development of Histologically Verified Thyroid Diseases in Women Operated for Breast Cancer: A Review of the Literature and a Case Series.

Authors:  Fausto Fama'; Alessandro Sindoni; Hui Sun; Hoon Yub Kim; Girolamo Geraci; Michele Rosario Colonna; Carmelo Mazzeo; Gabriela Brenta; Mariarosaria Galeano; Salvatore Benvenga; Gianlorenzo Dionigi
Journal:  J Clin Med       Date:  2022-06-01       Impact factor: 4.964

Review 2.  Thyroid Diseases and Breast Cancer.

Authors:  Enke Baldini; Augusto Lauro; Domenico Tripodi; Daniele Pironi; Maria Ida Amabile; Iulia Catalina Ferent; Eleonora Lori; Federica Gagliardi; Maria Irene Bellini; Flavio Forte; Patrizia Pacini; Vito Cantisani; Vito D'Andrea; Salvatore Sorrenti; Salvatore Ulisse
Journal:  J Pers Med       Date:  2022-01-25

Review 3.  The TSH/Thyroid Hormones Axis and Breast Cancer.

Authors:  Ioannis A Voutsadakis
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.